The first anti-CD19 antibody-drug conjugate for the treatment of large B cell lymphoma—Loncastuximab Tesirine-lpyl

doi:10.3969/j.issn.1672-3384.2021.11.003

PDF(494 KB)

Clinical Medication Journal ›› 2021, Vol. 19 ›› Issue (11) : 10-14. DOI: 10.3969/j.issn.1672-3384.2021.11.003

Lastest Drug

The first anti-CD19 antibody-drug conjugate for the treatment of large B cell lymphoma—Loncastuximab Tesirine-lpyl

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2021, 19(11): 10-14 https://doi.org/10.3969/j.issn.1672-3384.2021.11.003

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(494 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2021-09-10	2021-11-26
Issue Date
2021-11-26

Please choose a citation manager

Content to export